#antidepressants — Public Fediverse posts

DATE: September 8, 2026 at 11:00AM
SOURCE: PSYPOST.ORG

** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------

TITLE: Antidepressants show wide variation in physical side effects

URL: https://www.psypost.org/antidepressants-show-wide-variation-in-physical-side-effects/

Different antidepressants can have drastically different effects on a patient’s physical health, according to a recent review of medical research. Some medications cause substantial weight gain and increased blood pressure, while others lead to weight loss and lowered heart rates. The findings were published in The Lancet.

Millions of people rely on prescription medications to manage mental health conditions. Up to 17 percent of adults in Europe and North America currently take antidepressants. While these drugs are effective at treating mood disorders, they can also cause unintended bodily changes. These physical side effects are a common reason why people stop taking their prescribed treatments.

Medical guidelines recommend that doctors discuss potential physical changes with patients before starting a prescription. However, it can be difficult for physicians to provide precise comparisons between specific drugs.

Toby Pillinger and Atheeshaan Arumuham of King’s College London led the research team to address this knowledge gap. They worked alongside other international experts, including Orestis Efthimiou of the University of Bern, Oliver D. Howes of King’s College London, and Andrea Cipriani of the University of Oxford. The team wanted to determine exactly how different medications compare in terms of physical side effects. They also wanted to see if factors like age or starting weight influenced these bodily reactions.

To answer these questions, the researchers conducted a network meta-analysis. This type of statistical study pools data from multiple independent trials. It allows researchers to compare treatments that might never have been tested directly against each other in the same room. By linking trials through a common comparator, researchers can estimate how two different drugs would perform head-to-head.

The team gathered data from 151 randomized controlled trials and 17 government regulatory reports. The resulting large study included 58,534 participants. The researchers evaluated 30 different antidepressants prescribed for acute psychiatric treatment, which typically lasted about eight weeks.

The analysis revealed major differences in how these drugs affect body weight. People taking agomelatine experienced the most weight loss, losing an average of about 2.4 kilograms compared to those taking a placebo, an inactive control pill. On the other end of the spectrum, maprotiline and amitriptyline caused the most weight gain, adding up to 1.8 kilograms on average. This created a roughly four-kilogram gap between the highest and lowest weight-altering medications.

The researchers estimated that almost half of the people taking maprotiline or amitriptyline would gain a noticeable amount of weight. Medications that caused the most weight gain were generally those known to block specific histamine and serotonin receptors, which act as chemical docking stations in the brain. Over time, extra weight can elevate a person’s risk for metabolic issues and joint stress.

Cardiovascular changes also varied widely depending on the specific medication. Nortriptyline increased patients’ heart rates by an average of nearly 14 beats per minute. By contrast, fluvoxamine lowered heart rates by about eight beats per minute. This difference amounts to a 21-beat-per-minute gap between the two drugs.

Blood pressure effects showed a similar split among the evaluated medications. Amitriptyline raised systolic blood pressure, which measures the pressure in your arteries when your heart beats, by almost five millimeters of mercury. Nortriptyline lowered the same metric by over six millimeters of mercury. The researchers noted that these cardiovascular shifts could influence a patient’s long-term risk for heart disease, especially if the changes persist over several years.

The medications that increased blood pressure were largely serotonin-noradrenaline reuptake inhibitors, or tricyclic antidepressants. These drug classes share a mechanism that affects the neurotransmitter noradrenaline. This chemical messenger plays a well-documented role in blood pressure regulation.

The researchers also tracked metabolic markers like cholesterol and blood sugar. Paroxetine, duloxetine, desvenlafaxine, and venlafaxine were associated with measurable increases in total cholesterol. Duloxetine was also linked to increased blood glucose levels. These metabolic increases occurred even though the medications themselves generally caused patients to lose body weight.

Some medications also affected liver function tests. Duloxetine, desvenlafaxine, and levomilnacipran caused increases in the concentration of certain liver enzymes. These enzymes are proteins that help the organ filter blood and break down medications. While these enzyme elevations were substantial enough to measure, the researchers noted that the amounts were not high enough to pose an immediate medical threat to most patients.

The team did not find that any of the evaluated antidepressants altered heart rhythm intervals to a problematic degree. The medications also did not have a strong effect on sodium levels, potassium levels, or kidney function markers during the trial periods.

In a separate analysis, the researchers examined how patient characteristics influenced these side effects. They used a statistical technique called meta-regression to look for trends across the different study populations. They found that groups of patients with higher starting body weights experienced larger medication-induced increases in blood pressure and liver enzymes. Populations with a higher average age saw larger medication-induced increases in blood sugar.

Finally, the team wanted to know if experiencing physical side effects was linked to mental health improvements. In patients with severe psychiatric conditions like schizophrenia, past research has shown a correlation between metabolic disturbances and improved symptoms. To test this concept in depression, the researchers looked specifically at trials involving patients with major depressive disorder.

The researchers compared the change in depressive symptoms against changes in weight, cholesterol, and blood sugar across the studies. They did not find a correlation between improved mental health and metabolic side effects. This suggests that patients do not need to experience physical changes to get the mental health benefits of the medication.

A primary limitation of this research is the short duration of the included trials. Most studies lasted only eight weeks, meaning the long-term physical effects of these medications remain unconfirmed by this specific analysis. Some cardiovascular shifts might fade over time, while other metabolic changes could worsen over a period of years.

The trials also mostly included younger, relatively healthy individuals taking only one medication. This focus might obscure side effects that occur more frequently in older adults or people taking multiple drugs at once. Real-world observational data suggests that certain antidepressants might increase the risk of low sodium or heart rhythm problems in older populations. The researchers suggest that doctors should consider both clinical trial data and real-world observations when prescribing medications to older or medically vulnerable patients.

The study, “The effects of antidepressants on cardiometabolic and other physiological parameters: a systematic review and network meta-analysis,” was authored by Toby Pillinger, Atheeshaan Arumuham, Robert A McCutcheon, Enrico D’Ambrosio, Georgios Basdanis, Marco Branco, Richard Carr, Valeria Finelli, Toshi A Furukawa, Siobhan Gee, Adrian Heald, Sameer Jauhar, Zihan Ma, Valentina Mancini, Calum Moulton, Georgia Salanti, David M Taylor, Anneka Tomlinson, Allan H Young, Orestis Efthimiou, Oliver D Howes, and Andrea Cipriani.

URL: https://www.psypost.org/antidepressants-show-wide-variation-in-physical-side-effects/

-------------------------------------------------

Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org

Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

-------------------------------------------------

#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #Antidepressants #SideEffects #Cardiometabolic #DepressionTreatment #WeightChange #BloodPressure #Cholesterol #MetabolicHealth #NetworkMetaAnalysis #TheLancet

DATE: September 8, 2026 at 11:00AM
SOURCE: PSYPOST.ORG

** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------

TITLE: Antidepressants show wide variation in physical side effects

URL: https://www.psypost.org/antidepressants-show-wide-variation-in-physical-side-effects/

Different antidepressants can have drastically different effects on a patient’s physical health, according to a recent review of medical research. Some medications cause substantial weight gain and increased blood pressure, while others lead to weight loss and lowered heart rates. The findings were published in The Lancet.

Millions of people rely on prescription medications to manage mental health conditions. Up to 17 percent of adults in Europe and North America currently take antidepressants. While these drugs are effective at treating mood disorders, they can also cause unintended bodily changes. These physical side effects are a common reason why people stop taking their prescribed treatments.

Medical guidelines recommend that doctors discuss potential physical changes with patients before starting a prescription. However, it can be difficult for physicians to provide precise comparisons between specific drugs.

Toby Pillinger and Atheeshaan Arumuham of King’s College London led the research team to address this knowledge gap. They worked alongside other international experts, including Orestis Efthimiou of the University of Bern, Oliver D. Howes of King’s College London, and Andrea Cipriani of the University of Oxford. The team wanted to determine exactly how different medications compare in terms of physical side effects. They also wanted to see if factors like age or starting weight influenced these bodily reactions.

To answer these questions, the researchers conducted a network meta-analysis. This type of statistical study pools data from multiple independent trials. It allows researchers to compare treatments that might never have been tested directly against each other in the same room. By linking trials through a common comparator, researchers can estimate how two different drugs would perform head-to-head.

The team gathered data from 151 randomized controlled trials and 17 government regulatory reports. The resulting large study included 58,534 participants. The researchers evaluated 30 different antidepressants prescribed for acute psychiatric treatment, which typically lasted about eight weeks.

The analysis revealed major differences in how these drugs affect body weight. People taking agomelatine experienced the most weight loss, losing an average of about 2.4 kilograms compared to those taking a placebo, an inactive control pill. On the other end of the spectrum, maprotiline and amitriptyline caused the most weight gain, adding up to 1.8 kilograms on average. This created a roughly four-kilogram gap between the highest and lowest weight-altering medications.

The researchers estimated that almost half of the people taking maprotiline or amitriptyline would gain a noticeable amount of weight. Medications that caused the most weight gain were generally those known to block specific histamine and serotonin receptors, which act as chemical docking stations in the brain. Over time, extra weight can elevate a person’s risk for metabolic issues and joint stress.

Cardiovascular changes also varied widely depending on the specific medication. Nortriptyline increased patients’ heart rates by an average of nearly 14 beats per minute. By contrast, fluvoxamine lowered heart rates by about eight beats per minute. This difference amounts to a 21-beat-per-minute gap between the two drugs.

Blood pressure effects showed a similar split among the evaluated medications. Amitriptyline raised systolic blood pressure, which measures the pressure in your arteries when your heart beats, by almost five millimeters of mercury. Nortriptyline lowered the same metric by over six millimeters of mercury. The researchers noted that these cardiovascular shifts could influence a patient’s long-term risk for heart disease, especially if the changes persist over several years.

The medications that increased blood pressure were largely serotonin-noradrenaline reuptake inhibitors, or tricyclic antidepressants. These drug classes share a mechanism that affects the neurotransmitter noradrenaline. This chemical messenger plays a well-documented role in blood pressure regulation.

The researchers also tracked metabolic markers like cholesterol and blood sugar. Paroxetine, duloxetine, desvenlafaxine, and venlafaxine were associated with measurable increases in total cholesterol. Duloxetine was also linked to increased blood glucose levels. These metabolic increases occurred even though the medications themselves generally caused patients to lose body weight.

Some medications also affected liver function tests. Duloxetine, desvenlafaxine, and levomilnacipran caused increases in the concentration of certain liver enzymes. These enzymes are proteins that help the organ filter blood and break down medications. While these enzyme elevations were substantial enough to measure, the researchers noted that the amounts were not high enough to pose an immediate medical threat to most patients.

The team did not find that any of the evaluated antidepressants altered heart rhythm intervals to a problematic degree. The medications also did not have a strong effect on sodium levels, potassium levels, or kidney function markers during the trial periods.

In a separate analysis, the researchers examined how patient characteristics influenced these side effects. They used a statistical technique called meta-regression to look for trends across the different study populations. They found that groups of patients with higher starting body weights experienced larger medication-induced increases in blood pressure and liver enzymes. Populations with a higher average age saw larger medication-induced increases in blood sugar.

Finally, the team wanted to know if experiencing physical side effects was linked to mental health improvements. In patients with severe psychiatric conditions like schizophrenia, past research has shown a correlation between metabolic disturbances and improved symptoms. To test this concept in depression, the researchers looked specifically at trials involving patients with major depressive disorder.

The researchers compared the change in depressive symptoms against changes in weight, cholesterol, and blood sugar across the studies. They did not find a correlation between improved mental health and metabolic side effects. This suggests that patients do not need to experience physical changes to get the mental health benefits of the medication.

A primary limitation of this research is the short duration of the included trials. Most studies lasted only eight weeks, meaning the long-term physical effects of these medications remain unconfirmed by this specific analysis. Some cardiovascular shifts might fade over time, while other metabolic changes could worsen over a period of years.

The trials also mostly included younger, relatively healthy individuals taking only one medication. This focus might obscure side effects that occur more frequently in older adults or people taking multiple drugs at once. Real-world observational data suggests that certain antidepressants might increase the risk of low sodium or heart rhythm problems in older populations. The researchers suggest that doctors should consider both clinical trial data and real-world observations when prescribing medications to older or medically vulnerable patients.

The study, “The effects of antidepressants on cardiometabolic and other physiological parameters: a systematic review and network meta-analysis,” was authored by Toby Pillinger, Atheeshaan Arumuham, Robert A McCutcheon, Enrico D’Ambrosio, Georgios Basdanis, Marco Branco, Richard Carr, Valeria Finelli, Toshi A Furukawa, Siobhan Gee, Adrian Heald, Sameer Jauhar, Zihan Ma, Valentina Mancini, Calum Moulton, Georgia Salanti, David M Taylor, Anneka Tomlinson, Allan H Young, Orestis Efthimiou, Oliver D Howes, and Andrea Cipriani.

URL: https://www.psypost.org/antidepressants-show-wide-variation-in-physical-side-effects/

-------------------------------------------------

Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org

Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

-------------------------------------------------

#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #Antidepressants #SideEffects #Cardiometabolic #DepressionTreatment #WeightChange #BloodPressure #Cholesterol #MetabolicHealth #NetworkMetaAnalysis #TheLancet

DATE: September 8, 2026 at 11:00AM
SOURCE: PSYPOST.ORG

** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------

TITLE: Antidepressants show wide variation in physical side effects

URL: https://www.psypost.org/antidepressants-show-wide-variation-in-physical-side-effects/

Different antidepressants can have drastically different effects on a patient’s physical health, according to a recent review of medical research. Some medications cause substantial weight gain and increased blood pressure, while others lead to weight loss and lowered heart rates. The findings were published in The Lancet.

Millions of people rely on prescription medications to manage mental health conditions. Up to 17 percent of adults in Europe and North America currently take antidepressants. While these drugs are effective at treating mood disorders, they can also cause unintended bodily changes. These physical side effects are a common reason why people stop taking their prescribed treatments.

Medical guidelines recommend that doctors discuss potential physical changes with patients before starting a prescription. However, it can be difficult for physicians to provide precise comparisons between specific drugs.

Toby Pillinger and Atheeshaan Arumuham of King’s College London led the research team to address this knowledge gap. They worked alongside other international experts, including Orestis Efthimiou of the University of Bern, Oliver D. Howes of King’s College London, and Andrea Cipriani of the University of Oxford. The team wanted to determine exactly how different medications compare in terms of physical side effects. They also wanted to see if factors like age or starting weight influenced these bodily reactions.

To answer these questions, the researchers conducted a network meta-analysis. This type of statistical study pools data from multiple independent trials. It allows researchers to compare treatments that might never have been tested directly against each other in the same room. By linking trials through a common comparator, researchers can estimate how two different drugs would perform head-to-head.

The team gathered data from 151 randomized controlled trials and 17 government regulatory reports. The resulting large study included 58,534 participants. The researchers evaluated 30 different antidepressants prescribed for acute psychiatric treatment, which typically lasted about eight weeks.

The analysis revealed major differences in how these drugs affect body weight. People taking agomelatine experienced the most weight loss, losing an average of about 2.4 kilograms compared to those taking a placebo, an inactive control pill. On the other end of the spectrum, maprotiline and amitriptyline caused the most weight gain, adding up to 1.8 kilograms on average. This created a roughly four-kilogram gap between the highest and lowest weight-altering medications.

The researchers estimated that almost half of the people taking maprotiline or amitriptyline would gain a noticeable amount of weight. Medications that caused the most weight gain were generally those known to block specific histamine and serotonin receptors, which act as chemical docking stations in the brain. Over time, extra weight can elevate a person’s risk for metabolic issues and joint stress.

Cardiovascular changes also varied widely depending on the specific medication. Nortriptyline increased patients’ heart rates by an average of nearly 14 beats per minute. By contrast, fluvoxamine lowered heart rates by about eight beats per minute. This difference amounts to a 21-beat-per-minute gap between the two drugs.

Blood pressure effects showed a similar split among the evaluated medications. Amitriptyline raised systolic blood pressure, which measures the pressure in your arteries when your heart beats, by almost five millimeters of mercury. Nortriptyline lowered the same metric by over six millimeters of mercury. The researchers noted that these cardiovascular shifts could influence a patient’s long-term risk for heart disease, especially if the changes persist over several years.

The medications that increased blood pressure were largely serotonin-noradrenaline reuptake inhibitors, or tricyclic antidepressants. These drug classes share a mechanism that affects the neurotransmitter noradrenaline. This chemical messenger plays a well-documented role in blood pressure regulation.

The researchers also tracked metabolic markers like cholesterol and blood sugar. Paroxetine, duloxetine, desvenlafaxine, and venlafaxine were associated with measurable increases in total cholesterol. Duloxetine was also linked to increased blood glucose levels. These metabolic increases occurred even though the medications themselves generally caused patients to lose body weight.

Some medications also affected liver function tests. Duloxetine, desvenlafaxine, and levomilnacipran caused increases in the concentration of certain liver enzymes. These enzymes are proteins that help the organ filter blood and break down medications. While these enzyme elevations were substantial enough to measure, the researchers noted that the amounts were not high enough to pose an immediate medical threat to most patients.

The team did not find that any of the evaluated antidepressants altered heart rhythm intervals to a problematic degree. The medications also did not have a strong effect on sodium levels, potassium levels, or kidney function markers during the trial periods.

In a separate analysis, the researchers examined how patient characteristics influenced these side effects. They used a statistical technique called meta-regression to look for trends across the different study populations. They found that groups of patients with higher starting body weights experienced larger medication-induced increases in blood pressure and liver enzymes. Populations with a higher average age saw larger medication-induced increases in blood sugar.

Finally, the team wanted to know if experiencing physical side effects was linked to mental health improvements. In patients with severe psychiatric conditions like schizophrenia, past research has shown a correlation between metabolic disturbances and improved symptoms. To test this concept in depression, the researchers looked specifically at trials involving patients with major depressive disorder.

The researchers compared the change in depressive symptoms against changes in weight, cholesterol, and blood sugar across the studies. They did not find a correlation between improved mental health and metabolic side effects. This suggests that patients do not need to experience physical changes to get the mental health benefits of the medication.

A primary limitation of this research is the short duration of the included trials. Most studies lasted only eight weeks, meaning the long-term physical effects of these medications remain unconfirmed by this specific analysis. Some cardiovascular shifts might fade over time, while other metabolic changes could worsen over a period of years.

The trials also mostly included younger, relatively healthy individuals taking only one medication. This focus might obscure side effects that occur more frequently in older adults or people taking multiple drugs at once. Real-world observational data suggests that certain antidepressants might increase the risk of low sodium or heart rhythm problems in older populations. The researchers suggest that doctors should consider both clinical trial data and real-world observations when prescribing medications to older or medically vulnerable patients.

The study, “The effects of antidepressants on cardiometabolic and other physiological parameters: a systematic review and network meta-analysis,” was authored by Toby Pillinger, Atheeshaan Arumuham, Robert A McCutcheon, Enrico D’Ambrosio, Georgios Basdanis, Marco Branco, Richard Carr, Valeria Finelli, Toshi A Furukawa, Siobhan Gee, Adrian Heald, Sameer Jauhar, Zihan Ma, Valentina Mancini, Calum Moulton, Georgia Salanti, David M Taylor, Anneka Tomlinson, Allan H Young, Orestis Efthimiou, Oliver D Howes, and Andrea Cipriani.

URL: https://www.psypost.org/antidepressants-show-wide-variation-in-physical-side-effects/

-------------------------------------------------

Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org

Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

-------------------------------------------------

#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #Antidepressants #SideEffects #Cardiometabolic #DepressionTreatment #WeightChange #BloodPressure #Cholesterol #MetabolicHealth #NetworkMetaAnalysis #TheLancet

#MentalWealth #MentalHealth #GutHealth #Serotonin #Depression #Antidepressants #Wellbeing #MentalWellness #HealthAdvice #biohack #biohacking #biohacker #biohackingsecrets #GutHealthMatters #GutHealthy #GutHealthIsEverything #GutHealthDiet #GutHealthTips #GutHealthCoach #GaryBrecka #Tenex https://mastodon.social/@biohackingpathway/116559215705051526

I can’t even…

#RFKJr Blames Pills — Not #Guns — for #SchoolShootings

There is NO credible evidence that #antidepressants cause violence, but Kennedy now vows a “massive” effort to prove the failed theory.

#policy #law #Trump #ConspiracyTheories #disinformation #ChildEndangerment #PublicHealth #GunControl #GunLaws #Health #MentalHealth #science #medicine #USpol #SchoolShooting #MassShooting #GunViolence #EnoughIsEnough
https://www.motherjones.com/politics/2025/12/rfk-jr-mass-shootings-ssri-antidepressants/

From 619 Drugs to 1: Researchers Uncover Hidden Risk

Introduction: Addiction Risk in Commonly Prescribed Drugs

When you think of medication side effects, your mind probably goes to the warnings listed in commercials. Drowsiness, nausea, dizziness, etc. These are common, often manageable, and generally expected side effects of drugs.

But what about far more profound ones that can alter your behavior, strain your relationships, and impact your life?

A recent study delved into this very issue, analyzing VigiBase®, the World Health Organization’s global pharmacovigilance database, containing over 36 million adverse event reports, to uncover surprising links between everyday medications and the development of behavioral addictions.

The research sought to identify drugs where these life-altering risks are not officially listed, leaving us in the dark. This post will break down the most impactful findings from that detective work.

Takeaway 1: It’s Not Just the Usual Suspects Anymore

For years, the primary link between medication and behavioral addiction centered on a specific class of drugs: dopaminergic antagonists used to treat Parkinson’s disease.

The connection was so well-established that it was considered the main, and for many, the only, example of this phenomenon. This new study dramatically broadens that scope.

By analyzing reports from healthcare professionals worldwide, researchers identified seven classes of drugs associated with behavioral addictions, even though this risk is not officially listed as a side effect for them. These include: 

• Antidepressants 
• Antipsychotics (specifically, dopamine antagonists) 
• Antiepileptics 
• Benzodiazepines or related drugs 
• Psychostimulants 
• Retinoids 
• One antidiabetic drug

This finding is significant because it suggests the problem is far more widespread than previously understood. It potentially affects patients being treated for a wide range of common conditions.

Are you a professional looking to stay up-to-date with the latest information on, sex addiction, trauma, and mental health news and research? Or maybe you’re looking for continuing education courses?

Stay up-to-date with all of Dr. Jen’s work through her practice’s newsletter!

Takeaway 2: A Widely Used Antipsychotic Emerged as a Primary Concern

From an initial pool of 619 suspect medications reported at least five times, researchers applied a rigorous filtering process to hunt for the strongest signals. Ultimately, only one drug, Olanzapine, met all of the study’s highest evidence-based criteria. 

Olanzapine is a second-generation antipsychotic medication.

The study found that it had the most well-documented cases with strong evidence linking it to behavioral addiction. This evidence included reports where symptoms resolved after:

• The patient stopped taking the drug (a “positive dechallenge”)
• A significant statistical signal in the data
• Support from existing scientific publications

The study’s authors emphasized how their multi-step analysis narrowed the field to this single, compelling candidate: 

Our analysis allows to narrow down the search to include only the most thoroughly documented cases… This process culminated in reducing the initial count of 619 suspect to 1: Olanzapine. 

While Olanzapine was the only drug to meet every one of the study’s strictest criteria, the researchers noted that other antipsychotics also showed significant warning signs in the data. The specific behavioral addictions most strongly linked to Olanzapine included a range of behaviors such as binge eating, compulsive sexual behavior, compulsive shopping, and gambling disorder.

Takeaway 3: This Hidden Danger Isn’t Listed on the Drugs Official Label

The core purpose of the study was to identify drugs for which behavioral addiction is not listed as a known side effect in the official Summaries of Product Characteristics (SPCs). These are the detailed documents that guide doctors on a drug’s use and risks. 

The implication of this is critical: patients and even some doctors may be completely unaware of these potential risks when prescribing or taking these medications.

An individual experiencing a sudden onset of compulsive behavior might not connect it to their prescription, leading to confusion, distress, and delayed intervention. This research underscores the importance of “pharmacovigilance,” the ongoing science of monitoring drug safety after a medication is on the market.

It is a crucial tool for uncovering hidden patterns and rare side effects that may not have appeared in initial clinical trials.

Do you have enough hours for your LPC renewal? Are you in need of continuing education, but bored with the current offerings? Check out Dr. Weeks’ course on Cannabis Use Disorder, and other unique courses on her practice website.

Sexual Addiction Treatment Services has been approved by NBCC as an Approved Continuing Education Provider, ACEP No. 7250. Programs that do not qualify for NBCC credit are clearly identified. Sexual Addiction Treatment Services is solely responsible for all aspects of the programs.

Takeaway 4: The Brain Science is More Complex Than Just Dopamine

Addiction is often explained through the lens of the brain’s reward system, which is heavily driven by the neurotransmitter dopamine.

This is why dopaminergic drugs for Parkinson’s were the first to be linked to behavioral addictions. However, the study’s findings on drugs like Olanzapine suggest a counter-intuitive possibility: the mechanism might involve a different system entirely.

Researchers theorize that for some of these medications, the effect may be caused by their interaction with the serotonergic system. Specifically, the way these drugs block certain serotonin receptors (known as 5HT2A receptors) could be responsible for inducing compulsive behaviors. 

This finding deepens our scientific understanding of addiction. It demonstrates that the pathways to addictive behavior in the brain are incredibly complex and varied, and not solely reliant on the dopamine system that has long dominated the conversation.

Conclusion: A Call for Greater Awareness of Drugs Side Effects

This research serves as a powerful reminder that our understanding of medication side effects is constantly evolving. What is considered safe today may reveal hidden complexities tomorrow. Ongoing research and diligent reporting by healthcare professionals are essential tools for ensuring patient safety long after a drug has been approved. 

The study’s findings highlight a potential blind spot in patient care. Life-altering behavioral changes might be mistakenly attributed to personal failings rather than a medication’s side effect.

This leads to a vital question for all of us: Knowing that these risks can go unlisted, how can we foster better conversations between patients and doctors about unexpected changes in behavior? 

Do you feel your sexual behavior, or that of someone you love, is out of control? Consult with a professional.

Are you exploring your trauma? Do you feel your childhood experiences were detrimental to your current mental or physical health? Utilize this free, validated, self-report questionnaire to find out.

Take the Adverse Childhood Experience (ACE) Questionnaire

Are you looking for more reputable data-backed information on sexual addiction? The Mitigation Aide Research Archive is an excellent source for executive summaries of research studies.

#addiction #addictiveBehaviors #antidepressants #antidiabetics #antiepileptics #antipsychotics #benzodiasepines #dopamine #dopaminergicAntagonists #drugAddiction #drugUse #drugs #hiddenDangersInMedications #highRiskMedications #olanzapine #prescriptionDrugs #psychostimulants #retinoids #who #worldHealthOrganization